Joining the Global Effort to Combat the Mounting Threats of Infectious Diseases
At Appili, we have the opportunity to work with a broad range of organizations to support our expanding pipeline, including government agencies in both the U.S. and Canada that are working to prevent pandemics and to decrease bioterrorism threats. Global initiatives to combat antibiotic resistance, including the U.S.’s recently launched National Strategy to Combat Antibiotic-Resistant Bacteria, have provided us with collaborative opportunities and incentives that have supported the growth of our pipeline.
Our balanced-risk portfolio, stable funding structure, and experienced leadership team have made Appili a partner of choice for many organizations looking to advance anti-infective programs.
The NRC has provided support for several of our pipeline programs:
We in-licensed our ATI-1701 asset from the NRC, providing Appili with exclusive worldwide rights to develop and commercialize this tularemia vaccine
The NRC provided non-dilutive funding for our ATI-1503 negamycin program provided under the NRC-IRAP program
The National Institutes of Allergy and Infectious Disease (NIAID) of the National Institutes of Health has provided funding for the ATI-1503 program and is part of the collaboration among Appili and U.S. and Canadian governments to bring ATI-1701 to market.
The Defense Threat Reduction Agency (DTRA), part of the U.S. Department of Defense, has provided over $6M U.S. to date to support the development work for our ATI-1701 vaccine.
Additional support for our metronidazole program has come from:
Groupe Parima, our development and commercial manufacturing partner for ATI-1501
Other collaborators in our negamycin program include:
The U.S. Army’s Peer Reviewed Medical Research Program (PRMRP)
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
Innovacorp, one of our earliest investors, has been instrumental in providing early venture capital and ongoing counsel and support.
In addition to working with these organizations, as we progress our lead asset, ATI-1501, to market, we are actively seeking partners for commercialization of our lead program, as well as engaging with other biopharma companies and government organizations to identify additional in-licensing opportunities that meet our business criteria.